Key result
Quinoline derivatives demonstrate antiprion activity in ScN2a cells, mirroring antimalarial structure-activity relationships.
Why the study?
No pharmacological options currently exist for prion diseases caused by pathogenic misfolded prion proteins.
Quinoline derivatives demonstrate similar structure-activity relationships for both antiprion and antimalarial effects in cell models, suggesting overlapping molecular targets.
Potent antiprion quinoline activity remains preclinical; hypothesis-generating and should not yet inform clinical practice.
Prion diseases are invariably fatal neurodegenerative diseases, in which the infectious agent consists of PrP(Sc), a pathogenic misfolded isoform of the normal cellular prion protein (PrP(C)). Until now, no pharmacological options exist for these novel pathogens. Here we describe the screening of a series of polyquinolines and quinolines linked to a large variety of terminal groups for their ability to cure a persistently prion infected cell line (ScN2a). Several compounds showed antiprion activity in the nanomolar range. The most active molecule, named 42, had a half-effective concentration (EC50) for antiprion activity of 50 nM. In a library of quinoline derivatives we were able to identify several structure-activity relationships (SAR). Remarkably, antiprion SAR in ScN2a cells were similar to antimalarial SAR in a cell model of malaria, particularly for the sulfonamide quinoline derivatives, suggesting that some molecular targets of antiprion and antimalarial substances overlap.
No takes yet. Share an insight, caveat, or question.
Klingenstein et al. (2006) studied Prion diseases. Quinoline derivatives was evaluated on Antiprion activity in a persistently prion infected cell line (ScN2a). Quinoline derivatives demonstrated antiprion activity in ScN2a cells (molecule 42 EC50 of 50 nM), with structure-activity relationships similar to antimalarial effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: